Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 107,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

NCT05724797
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NRS-033, Placebo
Drug
Lead sponsor
Nirsum Labs
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 30, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Less Discomfort and Less Pharmacology. Cataract Surgery at Physiologic Intraocular Pressure (IOP)

NCT06325397
View directory record Official record
Conditions
Nuclear Cataract
Interventions
High Intraocular Pressure (IOP), Low Intraocular Pressure (IOP)
Other
Lead sponsor
Matthew Rauen
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Peer to Peer (P2P): Mental Health Interventions With Persons With Substance Use Disorders

NCT06803810
View directory record Official record
Conditions
Standard of Care, P2P Intervention
Interventions
P2P Intervention
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

NCT06369610
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Computed Tomography, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of PF708 and Forteo in Healthy Subjects

NCT02656810
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide
Drug
Lead sponsor
Pfenex, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-Method Early Intervention Program for Inhibited and Anxious Preschoolers

NCT03486860
View directory record Official record
Conditions
Behavioral Inhibition, Anxiety
Interventions
Parent Psychoeducation, Turtle Program
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
42 Months to 60 Months
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.

NCT00790660
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ASP1941, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 30, 2026, 10:27 AM EDT
Terminated Not applicable Interventional

Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT03102060
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient
Interventions
Dietary Intervention, Laboratory Biomarker Analysis
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

NCT02048020
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
Interventions
paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
Drug · Radiation · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 30, 2026, 10:27 AM EDT
Terminated Not applicable Interventional

Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis

NCT01286220
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
Dilute bleach baths, Water
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 30, 2026, 10:27 AM EDT
Suspended Phase 1 Interventional

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

NCT03970382
View directory record Official record
Conditions
Solid Tumor
Interventions
NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
Biological
Lead sponsor
PACT Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT02207504
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
Crizotinib, Enzalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

NCT03036904
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT03696784
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions
iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Study of Massage Therapy Within a Brain Tumor Setting

NCT00873184
View directory record Official record
Conditions
Brain Tumors
Interventions
Massage Therapy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

NCT03561584
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Sulfasalazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
15 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Increasing Minority Participation in Clinical Trials

NCT02600533
View directory record Official record
Conditions
Clinical Trial
Interventions
Video viewing group
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Comedy in Chemotherapy (COMIC) Study

NCT01037933
View directory record Official record
Conditions
Cancer, Chemotherapy
Interventions
Humor intervention, Non-humor intervention (distraction)
Other
Lead sponsor
Queen's Medical Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

NCT00293033
View directory record Official record
Conditions
Pain, Cancer
Interventions
BEMA™, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee

NCT00722852
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ketoprofen in Diractin®, Placebo
Drug
Lead sponsor
IDEA AG
Industry
Eligibility
46 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2009 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

NCT01795547
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847
View directory record Official record
Conditions
Frail Elderly, Aging, Immune Function, Muscle Function
Interventions
Ketone ester, Placebo Comparator: Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Novato, California • Farmington, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Not yet recruiting No phase listed Observational

A Post Market Trial Assessing the Accuracy of Normal Mode Reading vs. ProScan Reading With the NaviCam SB System. This is a Comparison of Retrospectively Obtained Capsule Endoscopy Videos With a New AI Reading Tool; no New Interventions Will be Completed.

NCT07633847
View directory record Official record
Conditions
Small Bowel Bleeding
Interventions
Video capsule endoscopy, Phase II = Data analysis by Independent Readers, Phase III = Data Analysis by Expert Readers
Device · Other
Lead sponsor
AnX Robotica Corp.
Industry
Eligibility
22 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New York, New York • Bedford, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 10:27 AM EDT